Human challenge study: Difference between revisions

Revision as of 10:29, 28 August 2021

Revision as of 10:36, 30 August 2021

Line 23:

===COVID-19===

{{See also|COVID-19 vaccine clinical research#ProposedTrial and challengeauthorization studiesstatus}}

Human challenge studies are under consideration to hasten the development of a [[COVID-19 vaccine]],<ref name=callaway/><ref name=cohen20/><ref>{{cite news |url=https://www.bbc.com/news/health-54612293 |title=UK plan to be first to run human challenge Covid trials |work=BBC News |date=20 October 2020}}</ref> including one proposal made by bioethicist [[Nir Eyal (bioethicist)|Nir Eyal]],<ref name=eyal/> and another by [[rubella]] vaccine inventor [[Stanley Plotkin]] with bioethicist [[Arthur Caplan]].<ref name=plotkin/> These authors propose that the multi-year duration and multinational ___location of a typical Phase III efficacy clinical trial will continue as usual, while people infected with COVID-19 will continue to suffer or die.<ref name=plotkin/> As an alternative based on emerging results from COVID-19 vaccine challenge studies, regulatory agencies could allow early [[Emergency use authorization|emergency use]] of the vaccine, while the challenge study continues collecting data for eventual licensure.<ref name=plotkin/>